JP7541505B2 - アルツハイマー病の治療及び予防方法 - Google Patents

アルツハイマー病の治療及び予防方法 Download PDF

Info

Publication number
JP7541505B2
JP7541505B2 JP2021503770A JP2021503770A JP7541505B2 JP 7541505 B2 JP7541505 B2 JP 7541505B2 JP 2021503770 A JP2021503770 A JP 2021503770A JP 2021503770 A JP2021503770 A JP 2021503770A JP 7541505 B2 JP7541505 B2 JP 7541505B2
Authority
JP
Japan
Prior art keywords
months
subject
composition
determined
placebo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021503770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532126A (ja
JP2021532126A5 (cg-RX-API-DMAC7.html
Inventor
ジョアン ラスマン,
チャド ジェイ. スワンソン,
ヨン チャン,
ショブハ ダーダ,
ジンピン ワン,
リン クレイマー,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2021532126A publication Critical patent/JP2021532126A/ja
Publication of JP2021532126A5 publication Critical patent/JP2021532126A5/ja
Priority to JP2024077300A priority Critical patent/JP7875901B2/ja
Application granted granted Critical
Publication of JP7541505B2 publication Critical patent/JP7541505B2/ja
Priority to JP2026031310A priority patent/JP2026097906A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2021503770A 2018-07-24 2019-07-23 アルツハイマー病の治療及び予防方法 Active JP7541505B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024077300A JP7875901B2 (ja) 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法
JP2026031310A JP2026097906A (ja) 2018-07-24 2026-02-27 アルツハイマー病の治療及び予防方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862702659P 2018-07-24 2018-07-24
US62/702,659 2018-07-24
US201862749614P 2018-10-23 2018-10-23
US62/749,614 2018-10-23
US201962824162P 2019-03-26 2019-03-26
US62/824,162 2019-03-26
US201962846902P 2019-05-13 2019-05-13
US62/846,902 2019-05-13
US201962874684P 2019-07-16 2019-07-16
US62/874,684 2019-07-16
PCT/US2019/043067 WO2020023530A2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024077300A Division JP7875901B2 (ja) 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法

Publications (3)

Publication Number Publication Date
JP2021532126A JP2021532126A (ja) 2021-11-25
JP2021532126A5 JP2021532126A5 (cg-RX-API-DMAC7.html) 2022-07-28
JP7541505B2 true JP7541505B2 (ja) 2024-08-28

Family

ID=67551415

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021503770A Active JP7541505B2 (ja) 2018-07-24 2019-07-23 アルツハイマー病の治療及び予防方法
JP2024077300A Active JP7875901B2 (ja) 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法
JP2026031310A Pending JP2026097906A (ja) 2018-07-24 2026-02-27 アルツハイマー病の治療及び予防方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024077300A Active JP7875901B2 (ja) 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法
JP2026031310A Pending JP2026097906A (ja) 2018-07-24 2026-02-27 アルツハイマー病の治療及び予防方法

Country Status (11)

Country Link
US (1) US20210324056A1 (cg-RX-API-DMAC7.html)
EP (1) EP3826674A2 (cg-RX-API-DMAC7.html)
JP (3) JP7541505B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210039402A (cg-RX-API-DMAC7.html)
CN (2) CN118924896A (cg-RX-API-DMAC7.html)
AU (2) AU2019309938B2 (cg-RX-API-DMAC7.html)
CA (1) CA3107370A1 (cg-RX-API-DMAC7.html)
IL (3) IL310132B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021000778A (cg-RX-API-DMAC7.html)
PH (1) PH12021500006A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020023530A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
PT4121007T (pt) * 2020-03-20 2025-09-25 Eisai R&D Man Co Ltd Formulações de anticorpo de protofibrila de péptido anti-beta amiloide de concentração alta e métodos de uso das mesmas
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
WO2022035758A1 (en) * 2020-08-12 2022-02-17 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
WO2023114586A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
KR20240142535A (ko) * 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081460A1 (en) 2016-10-27 2018-05-03 Eisai R&D Management Co., Ltd. Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) * 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
BRPI0906962B8 (pt) 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
WO2011106732A1 (en) * 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
EP2665716B1 (en) 2011-01-21 2017-03-08 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3405489A1 (en) * 2016-01-20 2018-11-28 Genentech, Inc. High dose treatments for alzheimer's disease
WO2017194789A1 (en) * 2016-05-13 2017-11-16 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081460A1 (en) 2016-10-27 2018-05-03 Eisai R&D Management Co., Ltd. Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
「EISAI AND BIOGEN ANNOUNCE POSITIVE TOPLINE RESULTS OF THE FINAL ANALYSIS FOR BAN2401 AT 18 MONTHS」のインターネットアーカイブ [オンライン],Eisai Co., Ltd. & Biogen Inc.,2018年07月10日,[検索日:2023年8月4日], <URL: https://web.archive.org/web/20180710034023/https://investors.biogen.com/news-releases/news-release-details/eisai-and-biogen-announce-positive-topline-results-final>

Also Published As

Publication number Publication date
MX2021000778A (es) 2021-03-31
PH12021500006A1 (en) 2021-09-13
US20210324056A1 (en) 2021-10-21
CA3107370A1 (en) 2020-01-30
IL310132B1 (en) 2025-11-01
AU2019309938A1 (en) 2021-03-11
BR112021001272A2 (pt) 2021-04-27
IL323583A (en) 2025-11-01
AU2019309938B2 (en) 2026-04-02
CN112805031A (zh) 2021-05-14
WO2020023530A2 (en) 2020-01-30
WO2020023530A3 (en) 2020-03-12
JP2024112859A (ja) 2024-08-21
JP2021532126A (ja) 2021-11-25
KR20210039402A (ko) 2021-04-09
IL310132B2 (en) 2026-03-01
IL280315B1 (en) 2024-02-01
TW202019471A (zh) 2020-06-01
IL280315B2 (en) 2024-06-01
EP3826674A2 (en) 2021-06-02
CN118924896A (zh) 2024-11-12
IL280315A (en) 2021-03-25
IL310132A (en) 2024-03-01
JP2026097906A (ja) 2026-06-16
JP7875901B2 (ja) 2026-06-18
AU2026204903A1 (en) 2026-07-09

Similar Documents

Publication Publication Date Title
JP2024112859A (ja) アルツハイマー病の治療及び予防方法
US20250163135A1 (en) Biomarkers for alzheimer&#39;s disease treatment
JP2025506389A (ja) p-タウ181レベルを使用した治療方法
JP2025539394A (ja) タウpetレベルを使用する治療の方法
AU2017347838B2 (en) Composition comprising an anti-Αβ protofibril antibody and a beta-secretase BACE1 inhibitor for the treatment of Alzheimer&#39;s disease
RU2832167C2 (ru) Способы лечения и предупреждения болезни альцгеймера
HK40118843A (en) Methods of treatment and prevention of alzheimer’s disease
BR122025003268A2 (pt) Métodos de tratamento e prevenção de doença de alzheimer
BR112021001272B1 (pt) Métodos de tratamento e prevenção de doença de alzheimer
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
CN118786141A (zh) 使用p-tau181水平的治疗方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240816

R150 Certificate of patent or registration of utility model

Ref document number: 7541505

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150